NASDAQ:LMAT - LeMaitre Vascular Stock Price, Price Target & More

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

LeMaitre Vascular declared a quarterly dividend on Monday, April 23rd. Investors of record on Tuesday, May 22nd will be given a dividend of $0.07 per share on Thursday, June 7th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date is Monday, May 21st. View LeMaitre Vascular's Dividend History.

LeMaitre Vascular declared that its Board of Directors has approved a share buyback plan on Friday, July 28th 2017, which allows the company to repurchase $7,500,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's leadership believes its shares are undervalued.

LeMaitre Vascular Inc (NASDAQ:LMAT) posted its quarterly earnings results on Wednesday, April, 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.21 by $0.02. The medical instruments supplier had revenue of $25.99 million for the quarter, compared to analysts' expectations of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The company's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.16 EPS. View LeMaitre Vascular's Earnings History.

LeMaitre Vascular issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share (EPS) guidance of $1.05-1.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98. The company issued revenue guidance of $106-109 million, compared to the consensus revenue estimate of $111.05 million.LeMaitre Vascular also updated its Q2 guidance to $0.41-0.43 EPS.

5 analysts have issued 1 year price targets for LeMaitre Vascular's shares. Their forecasts range from $31.00 to $40.00. On average, they expect LeMaitre Vascular's share price to reach $34.40 in the next twelve months. View Analyst Ratings for LeMaitre Vascular.

Some companies that are related to LeMaitre Vascular include NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), CryoLife (CRY), K2M Group (KTWO) and Cerus (CERS).

News stories about LMAT stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LeMaitre Vascular earned a daily sentiment score of 0.08 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 47.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

LeMaitre Vascular's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.08%), Dimensional Fund Advisors LP (5.20%), Epoch Investment Partners Inc. (3.99%), Thomson Horstmann & Bryant Inc. (1.78%), Allianz Asset Management GmbH (1.70%) and Northern Trust Corp (1.29%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

LMAT stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Allianz Asset Management GmbH, Biondo Investment Advisors LLC, Fiera Capital Corp, Thomson Horstmann & Bryant Inc. and Barclays PLC. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.

LMAT stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sensato Investors LLC, King Luther Capital Management Corp, BlackRock Inc., Epoch Investment Partners Inc., Campbell & CO Investment Adviser LLC, Dupont Capital Management Corp and Millennium Management LLC. View Insider Buying and Selling for LeMaitre Vascular.

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMAT stock can currently be purchased for approximately $34.44.

LeMaitre Vascular has a market capitalization of $665.11 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.